- Supported exchanges /
- F /
- 4SG.F
SOL-GEL TECHN. IS-10 (4SG F) stock market data APIs
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
SOL-GEL TECHN. IS-10 Financial Data Overview
0.57 | |
0.57 | |
- | |
0.57 | |
0.57 | |
0.274-1.42 | |
17 455 K | |
27 858 K | |
6 559 K | |
-0.35 | |
1.566 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
SOL-GEL TECHN. IS-10 Fundamental Data is available in our Financial Data APIs
- Net Revenue 6 559 K
- EBITDA -16 520 000
- Earnings Per Share -0.5
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get SOL-GEL TECHN. IS-10 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.21
Get SOL-GEL TECHN. IS-10 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: